A sustainable generics industry in the EU Posted 19/08/2011
Today, generic medicines play an essential role in treating disease by increasing the accessibility and affordability of modern day pharmaceuticals. It is therefore essential to ensure that generics can enter the market as soon as possible after patent and data exclusivity protections expire and compete effectively in order to maintain a sustainable generics industry.
The three pillars for obtaining such a sustainable generics industry are as follows: Fair access to market Fair pricing Fair competition The long-term sustainability of the generic medicines sector relies on fair prices and a level playing field. Acceptable margins across the entire generic medicines supply chain will be essential if their full value is to be realised. It is important to increase patient access to generic medicines and there are many benefits to be gained from their faster uptake. Treating them solely as a cost-saving mechanism will serve only to stifle their ability to deliver continued benefits long-term. Generic medicines provide an opportunity to obtain similar treatments at lower costs for patients and payers, while liberating budgets for financing new innovative medicines. However, in order to achieve these benefits there needs to be a level playing field and governmental policies which maintain a sustainable generics industry. Related articles Generic drugs – registration, quality, value and sustainability The role of generic drugs in the EU Registration procedures for generic drugs in the EU
Source: EGA, IMS Health
Comments (0)
Generics News Research General
- Clopidogrel goes off-patent: last of the old-st...Generics/General | Posted 18/05/2012
- Generic atorvastatin could save NHS GBP 350 mil...Generics/News | Posted 18/05/2012
- Can generic competition succeed at reducing cos...Generics/Research | Posted 11/05/2012
- Also noted on generics: 11 May 2012Generics/General | Posted 11/05/2012
Biosimilars News Research General
- Biosimilars approved and marketed in BelgiumBiosimilars/General | Posted 18/05/2012
- Biosimilar filgrastim provides cost savings for...Biosimilars/Research | Posted 11/05/2012
- US Supreme Court looks set to challenge Afforda...Biosimilars/General | Posted 18/05/2012
- Daiichi Sankyo and Coherus BioSciences make bio...Biosimilars/News | Posted 18/05/2012




